The Chinese drug delivery devices market is projected to reach $638.4m by 2023, according to a report by GlobalData.

Titled ‘China Drug Delivery Devices Market Outlook to 2023, – Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices’, the report states that the top 15 companies operating in the market space are overseas players.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Consumer demand for quality is the key factor responsible for the dominance of overseas players in the Chinese drug delivery devices market.

Despite the presence of several domestic companies, products sold by overseas players are perceived as being safer by doctors as they are fully approved by multiple regulatory authorities.

The drug delivery devices market includes four categories, namely infusion systems, metered-dose inhaler devices, central venous catheters, and needle-free injections.

The infusion systems category holds the biggest market share of 58% and was worth $285m in 2016.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Consumer demand for quality is the key factor responsible for the dominance of overseas players in the Chinese drug delivery devices market.”

The segment is expected to grow at a compound annual growth rate (CAGR) of 4.1% during the forecast period. Metered dose inhaler device category with a sales worth $178.8m in 2016 is projected to grow at a CAGR of 3.5%.

Central venous catheters segment recorded sales worth $25.3m in 2016, while the needle-free injections segment was worth $1.8m.

GlaxoSmithKline (GSK) is the biggest overseas player in the market and held a market share of 10.9% of the $490.9m market in 2016. The company achieved the dominance through aggressive pricing strategy and price reduction, states GlobalData Medical Devices analyst James Spencer.

Opaque and continually changing regulatory guidelines regarding commercialisation of devices pose challenges for investors. The market, however, is expected to grow at a CAGR of 3.8% during the forecast period despite the anticipated challenges.

Unit sales of drug delivery devices is forecast to increase from 27.2 million in 2016 and to 37.1 million in 2023, representing a CAGR of 4.5%. The rise in incidences of chronic diseases is expected to further drive demand, states Spencer.